Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

licensing opportunities for our programs."

Research and development expenses totaled $56.4 million in the second quarter of 2008, compared to $40.9 million in the second quarter of 2007. Research and development expenses in the first half of 2008 totaled $104.0 million, compared to $76.6 million in the first half of 2007. This increase in research and development expenses is primarily attributable to increased clinical trial costs related to the Phase 3 clinical program for lorcaserin hydrochloride, Arena's drug candidate for the treatment of obesity, and the APD125 Phase 2b trial for the treatment of insomnia. Research and development expenses in the first half of 2008 included $2.2 million in non-cash, share-based compensation expense, compared to $2.1 million in the first half of 2007. General and administrative expenses totaled $7.2 million in the second quarter of 2008, compared to $6.8 million in the second quarter of 2007. General and administrative expenses in the first half of 2008 totaled $16.0 million, compared to $11.8 million in the first half of 2007. This increase in general and administrative expenses is primarily attributable to increases in personnel-related expenses and patent costs. Total patent costs, including patent costs related to partnered programs, increased by $1.1 million in the first half of 2008 compared to the first half of 2007, while total personnel-related expenses increased by $1.4 million between these same periods. General and administrative expenses in the first half of 2008 included $2.1 million in non-cash, share-based compensation expense, compared to $2.0 million in the first half of 2007.

Interest and other income and expenses, net, in the second quarter and first half of 2008 included a $2.0 million non-cash charge as a reserve for a contingent liability for the possible settlement of a disagreement with one of Arena's two warrant holders from its series B redeemable convertible preferred stock financing. A
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Paul G. Allen Family Foundation announced today the award ... of researchers with projects at the frontier of one ... human brain cells in the laboratory. The projects are ... years.  "This new cohort of Allen ... the field of neuronal maturation is at the leading ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... May 7, 2015 after the close of the U.S. ... and webcast on Thursday, May 7, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... SAINT-MALO, FRANCE (PRWEB) April 30, 2015 ... States and at http://www.lespausa.com , Phytomer’s ... to sensitive and reactive skin while battling the ... inflammation. This restorative cream is formulated with star ... derived via biotechnology in a complex of soothing ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3
... Rochester,Medical Corporation (Nasdaq: ROCM ) will announce ... 2008. The Company will then,hold a quarterly conference call ... 4:00 p.m. central daylight time (5:00 p.m. eastern time)., ... can be accessed at,Rochester Medical,s website at http://www.rocm.com ...
... Single, Intramuscular (IM) Dose, Protects up to ... BROOK, N.J., April 22 Elusys Therapeutics, ... for the treatment of life-threatening infectious,diseases, today ... a,high-affinity humanized and deimmunized monoclonal antibody targeting ...
... UltraTape Industries, a division,of Delphon Industries and ... today the availability of sample kits for ... are currently 5,sample kits available including those ... Tapes, ESD Tapes, Medical and,Pharmaceutical Tapes, and ...
Cached Biology Technology:Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008 2Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 2Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 3UltraTape Announces Sample Kits Available for Purchase Through Website 2
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... non-profit American Association for the Advancement of Science (AAAS), ... Science Signaling , which focuses on new insights for ... See http://stke.sciencemag.org . Michael B. Yaffe, a ... and biological engineering at the Massachusetts Institute of Technology ...
... patients can be treated as closely as possible to ... a scientist told the 6th European Breast Cancer Conference ... Dr. Sibylle Loibl, Assistant Professor in Obstetrics and Gynaecology ... the German Breast Group, said that until now, evidence ...
... at the National Institute of Standards and Technology ... nanodroplet test tubes for studying individual proteins under ... living cell. By confining individual proteins in nanodroplets ... and structural changes of these biomolecules, says physicist ...
Cached Biology News:Science expands Science Signaling, featuring research related to medical advances, and more 2Science expands Science Signaling, featuring research related to medical advances, and more 3Science expands Science Signaling, featuring research related to medical advances, and more 4Science expands Science Signaling, featuring research related to medical advances, and more 5Pregnant patients lose out in breast cancer treatment; a new approach is needed 2'Nanodrop' test tubes created with a flip of a switch 2
... high-performance triple quadrupole 1200L sets the ... cost-conscious environment - incorporating the latest ... all liquid chromatography analytical needs. ... and the Transmission Quadrupole Analyzer provide ...
C1-inhibitor (C1-INH)...
... Certify products ATP-Free using Mo Bio luciferase ... ATP-Free certification service that will allow you to ... of accuracy and enable you to deliver them ... Mo Bios ATP detection limit is 3.5 x ...
Choriongonadotropin (human, hCG)...
Biology Products: